Pfizer’s RSV Vaccine Springs Another Surprise, This Time In Maternal Use

Could Seize Share From Sanofi - Analysts

 
• By Andrew McConaghie
  
Pregnant woman vaccine
Interim analysis of the Phase IIb study showed 85% efficacy against RSV infection for infants born to vaccinated mothers.
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip